EU Vaccine News
Following the EMA’s decision to bring forward the review of the AstraZeneca vaccine, EU member states are looking to get ahead in placing orders.
Over the weekend, news hit the wires that the Irish government was in talks to secure delivery of the yet to be authorized vaccine.
Pfizer Inc. supply issues experienced across member states has resulted in bid to secure supply from elsewhere.
Ireland expects to receive more than 3 million doses of the AstraZeneca vaccine. By receiving the vaccine ahead of the EMA recommendation and EU Commission authorization, it would mean that the vaccine could be administered immediately upon authorization.
Last week, the EMA had indicated that upon recommendation, the vaccine would be widely available by mid-February.
Ireland would therefore be around 2-weeks ahead of other EU member states. More importantly, Ireland may also avoid jostling with other EU member states for supply.
Having seen Britain go it alone on the vaccine front and approve the AstraZeneca vaccine late last year, Britain’s vaccination rates are well ahead of any of those seen across the EU.
According to the Bloomberg Vaccination Tracker, Ireland’s vaccination rate stood at 1.90 doses per 100 people as at 13th January.
While well short of the likes of the Israel, the U.A.E and even the UK and the U.S, its well ahead of many other EU member states.
To put it into perspective, the EU has a vaccination rat of 1.41 doses per 100 people as at 19th January.
Italy and Spain had rates of 2.01 and 2.08 doses per 100 as at 19th January.
By contrast, however, France had a vaccination rate of just 0.90 doses per 100. The numbers from the Netherlands were even more alarming. As at 19th January, the Netherlands had a vaccination rate of just 0.45 doses per 100 people.
With the broad spread of rates, it is not wholly surprising that some EU member states are looking to jump the gun in securing vaccine supply.
Ireland is certainly not amongst the worst affected by the COVID-19 pandemic.
At the time of writing, Ireland had a total of 176,839 total COVID-19 cases and 2,708 related deaths.
While well below the numbers reported from the likes of France, Germany, Italy, and Spain, there is some urgency globally to secure more vaccines.
New strains of the coronavirus have proved significantly more virulent and as a result could have a significant impact on economic conditions.
Germany has already announced an extension to its lockdown. Merkel also talked of a possible need to shut down borders in order to protect the country from new strains.
Without an adequate vaccine supply and vaccination drive, the impact of the new strains could be devastating.
COVID-19 numbers from the UK had certainly sent a warning to neighboring countries over the holidays.
Leading the charge geographically, by vaccination rate, continues to be Israel.
As at 19th January, Israel had a reported vaccination rate of 29.78 doses per 100, up from 25.91 as at 17th January.
The U.A.E continued to trail Israel in 2nd place, with a rate of 19.21 doses per 100.
Sitting behind Bahrain in 3rd was the UK, with a vaccination rate of 7.07 doses per 100. This was up from 6.45 doses per 100 as at 17th January.
Looking at the numbers, A marked increase in vaccination rates is going to be needed to support a speedier economic recovery.
Further extensions to existing lockdown periods could begin to hit the prospects of a 2nd quarter recovery.
While we see economic divergence globally, stemming from marked differences in vaccination rates, the same is likely within the EU.
For the Eurozone economic outlook, France, Germany, Italy, Spain, and the Netherlands will need to materially ramp up vaccinations.
It will be interesting to see whether the issue is raised during the ECB press conference tomorrow. How does the ECB see growth when considering the divergence in vaccination rates across member states?
For a full breakdown of vaccination rates by country, please visit Bloomberg Vaccination Tracker page here.
The Latest COVID-19 Numbers
At the time of writing, there were a total of 96,625,755 confirmed COVID-19 cases and 2,065,698 related deaths.
By geography, the U.S had reported 24,806,964 cases and 411,486 COVID-19 related deaths.
India reporting 10,596,442 cases, with Brazil reporting 8,575,742 cases.
Sitting behind Russia (3,612,800) remained the UK (3,466,849).
France (2,938,333), Italy (2,400,598), Spain (2,370,742), and Germany (2,071,473) reported a combined 9,781,146 cases.
The AstraZeneca vaccine remains the key to bringing the pandemic under control near-term. This is largely due to an expected abundance of supply.
When considering the current vaccination rates, however, there is one other factor to consider.
Pfizer Inc., Moderna Inc., and AstraZeneca’s vaccines are 2-dose vaccines. This means that another round of vaccines is going to be needed for effective protection against the virus.
When considering current vaccination rates, some of the more adversely affected nations may not be anywhere 50% vaccinated before the 2nd quarter.
This is yet another factor for the markets to consider in terms of any economic recovery.
The availability of a single dose vaccine may not be far off, with Johnson & Johnson set to release data imminently. In all reality, however, supply constraints could limit the availability of a single dose vaccine beyond U.S borders.
Johnson & Johnson Numbers
Johnson & Johnson had previously projected to deliver 12 million doses by the end of February and 100 million doses by the end of June.
According to recent reports, however, Johnson & Johnson may a number of months behind.
That suggests that 1 billion doses by the end of 2021 may also be an ambitious target.
Pfizer Inc., Moderna Inc., AstraZeneca, Sputnik V, and China’s two vaccines will be key near-term. Ultimately, however, it will likely be a single dose vaccine that brings an end to the COVID-19 pandemic.
Availability across the globe is going to be needed, however, for the pandemic to truly come to an end.
As we have seen in the early days of the COVID-19 vaccines, richer nations have cornered much of the vaccine supply.
This will also need to change for the number of new cases across the globe to begin falling.